SubMagna HMW

12/15/2025

🔬 The Science of Absorption: What Makes SubMagna HMW Different?

For high-molecular-weight molecules, base choice defines sublingual success. SubMagna HMW uses a three-part mechanism engineered for enhanced permeation:
🔬 Anhydrous Base, Emulsion: Forms an immediate emulsion upon contact with saliva, boosting API solubility and dispersibility.
🔬 Mucoadhesion: Proprietary properties increase contact time with the sublingual mucosa, maximizing absorption.
🔬 Permeation Enhancement: Specifically designed to aid the transport of larger molecular weight medications, like peptides and GLP-1s.

*Compounded medications are not reviewed by FDA for safety of efficacy

12/11/2025

🔥 Need a compounding pharmacy that works with SubMagna® HMW? 🔥

SubMagna® HMW isn’t just another base — it’s a state-of-the-art sublingual compounding platform pharmacists use to deliver high-molecular-weight and custom medication suspensions under the tongue. It’s available at an expanding network of pharmacies around the world.

💡 Whether you’re looking for advanced sublingual delivery options for hormones, peptides, GLP-1s, ED meds, LDN, headache therapies, vitamins, hospice care meds, etc., there are pharmacies out there compounding with SubMagna® HMW.

👉 Find one near you: https://submagna.com/find_a_pharmacy/
and see who’s compounding with SubMagna® HMW and is also a licensee of Kingdom Licensing (www.kingdomlicensing.com).

Find a compounding pharmacy near you that uses SubMagna® HMW. These U.S. pharmacies are also licensees of Kingdom Licensing.

12/08/2025

⚠️ Important Drug-Safety Alert for Our Community

The FDA and Novo Nordisk have issued a warning about counterfeit Ozempic (semaglutide) 1 mg injections circulating through unauthorized channels. These falsified products may contain the wrong ingredients, unsafe contaminants, or no active ingredient at all — and the needles packaged with them may not even be sterile. Serious harm can occur when patients unknowingly use products outside legitimate pharmacy supply chains.

At Kingdom Investment Holdings, we stand firmly on the side of integrity, traceability, and pharmacist-controlled quality. This is also why we continue to support compounded sublingual semaglutide in SubMagna® HMW through licensed pharmacies only. When prescribed appropriately and prepared under 503A standards, the sublingual format eliminates injection-related risks altogether while maintaining a fully transparent and auditable chain of custody.

Our position is straightforward:

Obtain semaglutide — branded injectable or compounded sublingual (or other) - only from licensed, authorized pharmacies.

Avoid any product sold online without a prescription or outside the controls of a legitimate pharmacy.

Report any suspected counterfeit packaging, lot numbers, or unusual clinical responses.

The rise in counterfeit injectables underscores how essential high-integrity compounding and strong supply-chain governance really are. SubMagna HMW was designed to give prescribers and patients an alternative route that is needle-free, adherent, and controlled from start to finish.

Patient safety isn’t negotiable.

https://www.drugs.com/fda/novo-nordisk-warns-consumers-counterfeit-ozempic-semaglutide-1-mg-us-14780.html

SubMagna HMW Richie's Specialty Pharmacy

PLAINSBORO, NJ, December 5, 2025 - FDA recently seized dozens of units of counterfeit Ozempic (semaglutide) injection 1 mg distributed illegally outside of Novo Nordisk’s authorized supply chain. The US Food and Drug Administration (FDA) has also updated its website with information about these co...

11/25/2025

Curious what everyone’s talking about with SubMagna® HMW and sublingual compounding? 👀

If you’re a pharmacist or prescriber and want to dig in, start here:

PCCA

11/25/2025

There’s a new addition inside the SubMagna® HMW portfolio.

At the request of healthcare providers, some pharmacies are now preparing compounded Suzetrigine in SubMagna® HMW, bringing this permeation-enhancing, self-emulsifying sublingual base to another emerging therapeutic category. It's simple - grind up the commercially available Suzetrigine tablet, add flavoring and SubMagna® HMW and you're there.

As always, SubMagna® HMW supports formulators who need:

• A stable, anhydrous suspension platform
• Rapid self-emulsification on contact with saliva
• Enhanced mucosal contact time
• Improved wetting and dispersibility for low-solubility APIs

This new formula reflects exactly what SubMagna® was built for - expanding the range of actives that can be explored via the sublingual route.

If your pharmacy is interested in incorporating advanced sublingual formulations into your workflow, visit www.SubMagna.com.

Compounded medications are not reviewed by the FDA for safety or efficacy. Formulations using SubMagna® HMW must be prepared by licensed compounding pharmacies in accordance with all state and federal regulations.

PCCA Kingdom Investment Holdings

JOURNAVX is an oral nonopioid indicated for the treatment of moderate-to-severe acute pain in adults—the first and only oral pain signal inhibitor highly selective for NaV1.81

11/10/2025

With new agreements from President Donald Trump promising lower prices on popular weight-loss drugs, the use of GLP-1 medications such as Ozempic and Mounjaro could soon surge even higher.

10/22/2025

https://www.independent.co.uk/news/world/americas/wegovy-weight-loss-injections-states-cost-b2849330.html

At least four states are trying to slash weight loss drug coverage

10/19/2025

🌍 From Texas to Tokyo - SubMagna® HMW is changing how the world compounds.

Any pharmacy, anywhere in the world, can use SubMagna® HMW - and frankly, everyone should. Every prescriber should DEMAND SubMagna® HMW be a part a compounded prescribed sublingual.

This innovative sublingual delivery base helps eliminate needles and improves sublingual delivery of Semaglutide, Sermorelin, NAD+ and so much more.

Innovation doesn’t have borders. Neither should better medicine.
👉 Learn more at www.SubMagna.com

Compounded medications are not reviewed by FDA for safety or efficacy.

Shark Tank Flamingo Charger Kingdom Investment Holdings Richie's Specialty Pharmacy PCCA RISE Institute for Compounding

10/12/2025

Where innovation meets impact. 💡❤️

At PCCA International 2025, SubMagna® HMW proudly stood alongside Smith Baggett, owner of Flamingo Charger (yes - the Shark Tank legend himself), and our friends at Bassagel, spotlighting how compounding innovation can fuel global philanthropy.

💥 Every share of this post on Facebook = $50 donated to the RISE Institute for Compounding, up to $50,000 total through October 15, 2025.

Together, we’re advancing patient care, empowering compounding pharmacies worldwide, and giving back to the profession that gives so much.

Let’s prove that innovation isn’t just about better medicine - it’s about better impact. 🌍

👉 Share this post.
👉 Tag your peers.
👉 Be part of the movement.



https://www.riseinstituteforcompounding.org/

09/27/2025

💡 GLP-1 medications are doing more than weight loss. They help with blood sugar, heart health, and may even reduce inflammation. Early research shows potential benefits in lupus and lupus nephritis - check out the article referenced!

For those wanting a needle-free option, some pharmacies offer compounded sublingual Semaglutide in SubMagna® HMW — simple and convenient under-the-tongue dosing.

👉 Learn more at www.subsema.com
| www.submagna.com

Compounded medications are not reviewed by FDA for safety or efficacy.



https://www.medpagetoday.com/rheumatology/lupus/117674?xid

It's getting harder to argue against these products as wonder drugs

09/23/2025

💡 Have Psoriasis?

GLP-1 medications like Semaglutide aren’t just about weight loss.

✨ New research shows they may also help with skin conditions such as psoriasis.

Pharmacies worldwide are compounding Semaglutide in SubMagna® HMW — a simple, needle-free sublingual option that makes access easier and more affordable.

👉 Learn more: www.SubSema.com and| www.SubMagna.com

⚠️ Compounded medications are not reviewed by the FDA for safety or efficacy.

Psoriasis is associated with cardiometabolic and psychiatric comorbidity. The anti-obesity and anti-diabetes glucagon-like peptide-1 receptor agonists (GLP

09/16/2025

Why might a compounded semaglutide dose look higher?

A weekly 7.2 mg subcutaneous dose (≈ 89% bioavailability) equates to ~6.4 mg absorbed. Assuming ~10% compounded sublingual absorption in SubMagna® HMW, an estimated 9.15 mg daily dose is needed to reach similar exposure. The latter is focused on estimates related to compounded drug products containing Semaglutide in SubMagna® HMW.

📌 Learn more: www.subsema.com and www.submagna.com

⚠️ Compounded medications are not FDA-reviewed for safety or efficacy. Sublingual absorption estimates are just that - estimates.

PCCA

Semaglutide 7·2 mg was superior to placebo and 2·4 mg for bodyweight reduction in adults with obesity, while retaining a favourable risk–benefit profile.